8-K

                       SECURITIES AND EXCHANGE COMMISSION
                              WASHINGTON, DC 20549

                                    FORM 8-K

                                 CURRENT REPORT
                     PURSUANT TO SECTION 13 OR 15 (d) OF THE
                         SECURITIES EXCHANGE ACT OF 1934

       Date of Report (Date of earliest event reported): March 30, 2004

                            POINT THERAPEUTICS, INC.
               (Exact Name of Registrant as Specified in Charter)


                       DELAWARE                    0-19410
           (State or Other Jurisdiction    (Commission File Number)
                   of Incorporation)

                 125 SUMMER STREET, BOSTON, MASSACHUSETTS 02110
                    (Address of Principal Executive Offices)

       Registrant's telephone number, including area code: (617) 933-2130

                                       N/A

          (Former Name or Former Address, if Changed Since Last Report)





Item 5.  Other Events and Regulation FD Disclosure.


             Point Therapeutics, Inc. issued a press release on March 30,
             2004 announcing the presentation of study data on its lead
             product candidate PT-100, in a poster session of the 2004
             American Association of Cancer Research (AACR) Annual Meeting
             in Orlando, Florida.

             A copy of the press release dated March 30, 2004 is being filed
             as Exhibit 99.1 to this Current Report on Form 8-K.


Item 7.  Financial Statements and Exhibits.

         (c) Exhibits.

         99.1 - Press release issued by Point Therapeutics, Inc., dated
         March 30, 2004.




SIGNATURES

     Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                  POINT THERAPEUTICS, INC.


March 30, 2004                            By:/s/ Donald R. Kiepert, Jr.
                                          -------------------------
                                  Name:   Donald R. Kiepert, Jr.
                                  Title:  President, Chief Executive Officer





                                  EXHIBIT INDEX

The following exhibit is filed herewith:

Exhibit     Description
- -------     -----------
99.1        Press release issued by Point Therapeutics, Inc. on March 30, 2004
            announcing the presentation of study data on its lead product
            candidate PT-100, in a poster session of the 2004 American
            Association of Cancer Research (AACR) Annual Meeting in Orlando,
            Florida.

EX-99.1

                                                                    Exhibit 99.1

Point Therapeutics Reports Data Showing Enhanced Preclinical Anti-Tumor
             Activity of Gemcitabine Combined with PT-100

    BOSTON--(BUSINESS WIRE)--March 30, 2004--Point Therapeutics, Inc.
(OTC Bulletin Board: POTP) today announced the presentation of study
data on lead product candidate PT-100, demonstrating preclinical tumor
growth suppression and enhancement of anti-tumor activity when
combined with the chemotherapy agents gemcitabine or docetaxel. These
results were revealed today in a poster session of the 2004 American
Association of Cancer Research (AACR) Annual Meeting in Orlando,
Florida.
    Study results showed that the combination of PT-100 with
gemcitabine was highly effective in reducing tumor burden. Every dose
of gemcitabine in the study (30mg/kg, 60 mg/kg and 120 mg/kg) showed
significantly (p less than 0.05) greater anti-tumor effect when
combined with PT-100 than either agent alone. PT-100 alone did not
cause any tumor rejection, and gemcitabine alone caused rejection
rates of approximately 20%. Combination treatment, however, caused
rejection in 40-50% of mice by day 25 after tumor inoculation. No
relapses were observed in the combination-treated mice over a further
30 days.
    Additional results demonstrated a greatly improved anti-tumor
effect when PT-100 was combined with docetaxel in the treatment of
mice bearing human non-small cell lung carcinoma (NSCLC) xenografts.
By day 50 after tumor inoculation, treatment with PT-100 and docetaxel
resulted in an 88 % reduction in tumor size compared with reductions
of 66% and 50%, respectively, in mice treated with PT-100 and
docetaxel as single agents.
    Previous study results investigating PT-100 and cisplatin
combination therapy demonstrated similarly increased tumor rejection
frequency, in this case, from 20% with cisplatin alone to 50% with
inclusion of PT-100. In both the cisplatin and gemcitabine studies,
mice were specifically immune to rechallenge with the tumor type that
they were originally inoculated with.
    The authors conclude that PT-100 is an anticancer agent with a
unique mechanism of action and the potential to enhance the activity
of commonly used chemotherapy regimens. "The tumor rejection rates
seen when PT-100 was used in combination with gemcitabine and other
chemotherapeutic agents were significant, and clearly superior to
those seen with the chemotherapy agents alone," said study author Dr.
Barry Jones, Senior Vice President of Research at Point. "These
results support our belief that PT-100 has the potential to become an
important treatment option for cancer patients receiving chemotherapy,
possibly enhancing current therapies as well as providing the
hematopoietic support that we have previously observed in pre-clinical
animal models."
    Point Therapeutics is using these findings to guide the design of
its Phase 2 clinical program, investigating the use of PT-100 in
combination with various chemotherapeutics agents. The Company has
already initiated a single-arm, two-stage Phase 2 clinical trial of
PT-100 for the treatment of advanced non-small cell lung cancer
(NSCLC). The study is designed to evaluate the anti-tumor and
hematopoietic activity of PT-100 in combination with Taxotere(R) in
Stage IIIb/IV NSCLC patients.

    About Point Therapeutics, Inc.:

    Point is a Boston-based biopharmaceutical company developing small
molecule drugs for the treatment of a variety of cancerous tumors and
certain hematopoietic disorders. Point's lead product candidate,
PT-100, has the potential to inhibit the growth of certain cancerous
tumors.
    In 2004, Point expects to initiate four Phase 2 clinical studies
in three different oncology indications. The first Phase 2 study has
been initiated and is evaluating PT-100 in combination with
Taxotere(R) in patients with non-small cell lung cancer. The other
planned trials will study PT-100 in metastatic melanoma in combination
with cisplatin, as a single-agent therapeutic in metastatic melanoma,
and in chronic lymphocytic leukemia in combination with Rituxan(R).
Point is currently testing PT-100 in combination with Rituxan(R) in a
Phase 1 human clinical study in patients with hematologic
malignancies, such as non-Hodgkin's lymphoma. Point is also developing
PT-100 as a potential therapy for the treatment of hematopoietic
disorders caused by chemotherapy treatments.
    Certain statements contained herein are not strictly historical
and are "forward looking" statements as defined in the Private
Securities Litigation Reform Act of 1995. This information includes
statements on the prospects for our drug development activities and
results of operations based on our current expectations, such as
statements regarding certain milestones with respect to our clinical
program and our product candidates. Forward-looking statements are
statements that are not historical facts, and can be identified by,
among other things, the use of forward-looking language, such as
"believe," "expect," "may," "will," "should," "seeks," "plans,"
"schedule to," "anticipates" or "intends" or the negative of those
terms, or other variations of those terms of comparable language, or
by discussions of strategy or intentions. A number of important
factors could cause actual results to differ materially from those
projected or suggested in the forward looking statement, including,
but not limited to, the ability of Point to (i) successfully develop
products, (ii) obtain the necessary governmental approvals, (iii)
effectively commercialize any products developed before its
competitors and (iv) obtain and enforce intellectual property rights,
as well as the risk factors described in Point's Annual Report on Form
10-K for the fiscal year ended December 31, 2003, filed with the
Securities and Exchange Commission on March 16, 2004 and from time to
time in Point's other reports filed with the Securities and Exchange
Commission.

    CONTACT: Point Therapeutics, Inc.
             Richard N. Small, 617-933-2136
             or
             Investor Relations:
             The Trout Group
             Ritu Baral, 212-477-4007 ext. 25